Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Important milestone: Bronchitol approved by NICE in U.K.

The National Institute for Health and Clinical Excellence (NICE) in the U.K. has issued a positive recommendation for Bronchitol®, clearing the way for reimbursement by the National Health Service.

Bronchitol listed on PBS for cystic fibrosis

A drug discovered and developed in Australia has been listed on the PBS for the treatment of cystic fibrosis.

Pharmaxis announces US$40 million financing agreement with NovaQuest

Pharmaxis is pleased to announce the signing of a Financing Agreement with NovaQuest under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for CF in the EU and US.

Pharmaxis appoints Gary Phillips as new CEO

The Pharmaxis board has appointed Mr. Gary Phillips to the position of Chief Executive Officer.